FDA Adverse Event Injury Summary report: N

ELUVIA?

MDR report key: 22136407 · Received June 3, 2025

Report

Report Number
2124215-2025-35942
Event Type
Injury
Date Received
June 3, 2025
Date of Event
December 11, 2021
Report Date
June 3, 2025
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NIU
UDI-DI
08714729876618
PMA / PMN Number
P180011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AR, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Description of Event or Problem · 0

IT WAS REPORTED THAT THERE WAS OCCLUSION OF THE TARGET LESION THREE MONTHS POST-TREATMENT WITH ELUVIA WHERE ADDITIONAL INTERVENTION WAS PERFORMED. THE SUBJECT UNDERWENT TREATMENT WITH ELUVIA DRUG-ELUTING STENTS ON (B)(6) 2021 AS A PART OF A CLINICAL TRIAL. THE TARGET LESION WAS IN THE LEFT PROXIMAL SUPERFICIAL FEMORAL ARTERY, LEFT MID SUPERFICIAL FEMORAL ARTERY AND LEFT DISTAL SUPERFICIAL FEMORAL ARTERY. THE LESION WAS DESCRIBED AS 7 MM PROXIMAL REFERENCE VESSEL DIAMETER AND 7 MM DISTAL REFERENCE VESSEL DIAMETER WITH 260 MM LESION LENGTH; 100% STENOSIS AND WAS CLASSIFIED AS TASC II D LESION. PRIOR TO THE TARGET LESION TREATMENT, PRE-DILATION WAS PERFORMED USING 4 MM X 200 MM ARMADA 18 PTA BALLOON. TREATMENT OF THE TARGET LESION WAS PERFORMED BY THE PLACEMENT OF 6 MM X 120 MM, 6 MM X 120 MM, 7 MM X 80 MM ELUVIA DRUG-ELUTING STENTS. FOLLOWING, POST-DILATION WAS PERFORMED USING 5 MM X 150 MM, AND 6 MM X 80 MM STERLING OTW PTA BALLOONS. THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 0%. ON THE SAME DAY, THE SUBJECT WAS DISCHARGED FROM THE HOSPITAL ON CLOPIDOGREL AND ASPIRIN. ON (B)(6) 2021, THE SUBJECT WAS NOTED WITH SYMPTOMS RELATED TO OCCLUSION OF THE LEFT SUPERFICIAL FEMORAL ARTERY. ON (B)(6) 2021, THE SUBJECT WAS HOSPITALIZED FOR FURTHER EVALUATION AND TREATMENT. ON THE SAME DAY, BILATERAL LOWER LIMB ANGIOGRAPHY REVEALED LEFT LEG IN-STENT OCCLUSION OF SUPERFICIAL FEMORAL ARTERY AND OCCLUSION OF P1 AND P2 SEGMENTS OF POPLITEAL ARTERY. NO SIGNIFICANT STENOSIS OF PROFUNDA FEMORIS ARTERY, ANTERIOR TIBIAL ARTERY, TIBIAL PERONEAL TRUNK OR PERONEAL ARTERY, BUT DID REVEAL OCCLUSION OF PATENT POSTERIOR TIBIAL ARTERY. ON (B)(6) 2021, 82 DAYS POST- INDEX PROCEDURE, OCCLUSION NOTED IN LEFT PROXIMAL, MID AND DISTAL SUPERFICIAL FEMORAL ARTERY WAS TREATED BY JETSTREAM ATHERECTOMY FOLLOWED BY BALLOON ANGIOPLASTY USING 6 MM X 220 MM STERLING BALLON. POST PROCEDURE, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 0 PERCENT. IN ADDITION, OCCLUSION NOTED IN THE LEFT PROXIMAL AND MID POPLITEAL ARTERY WAS TREATED BY 5 MM X 100 MM STERLING BALLOON FOLLOWED BY 5.5 MM X 100 MM SUPERA STENT PLACEMENT. POST TREATMENT, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 0 PERCENT. THE SUBJECT WAS DISCHARGED ON CLOPIDOGREL AND APIXABAN.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
358285 ELUVIA? STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING NIU BOSTON SCIENTIFIC CORPORATION H74939294601210 0027518000 08714729876618

Patients

Seq Age Sex Outcome Treatment
1 68 YR Female Required Intervention| H